Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions

NCT01464593 is registered in ClinicalTrials.gov with Imunon as lead sponsor.

NCT NCT01464593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01464593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions
Lead sponsor
Imunon
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2011
Completion date
June 30, 2013
Enrollment
2 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer liver metastasis